Solid Biosciences (SLDB) shared that the U.S. Department of Health and Human Services officially added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, or RUSP, the list of conditions recommended for universal newborn screening across the United States. Adding Duchenne to the RUSP is expected to accelerate detection efforts, leading to earlier access to specialists and supportive intervention and treatment options.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- HHS adds Duchenne muscular dystrophy to recommended screening panel
- Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Progress Drive Buy Rating
- Needham starts Solid Biosciences at Buy on opening in DMD market
- Solid Biosciences initiated with a Buy at Needham
- Solid Biosciences receives Rare Pediatric Disease designation of SGT-212